Results 31 to 40 of about 19,808 (220)

Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy

Pharmaceuticals, 2023
Possibilities to improve the therapeutic efficacy of Lu-177–PSMA-617 radionuclide therapy by modulation of target expression are being investigated.
Roswitha Runge, Anne Naumann, Matthias Miederer, Joerg Kotzerke, Claudia Brogsitter   +4 more
doaj   +1 more source

PET studies of the serotonin system in major depression and its treatment [PDF]

, 2014
The serotonin system has been implicated in major depression since the 1960s, mainly based on the serotonin enhancing properties of antidepressants.
Tiger, Mikael
core   +1 more source

Fluorine‐18‐Labeled Nucleotide Analogs Targeting Ecto‐5'‐Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors

Angewandte Chemie, EarlyView.
Fluorine‐18‐labeled CD73 inhibitor [18F]PSB‐19427 enables noninvasive PET mapping of CD73 overexpression in triple‐negative breast (TNBC) and pancreatic cancer. For [18F]PSB‐19427, specific binding in human tumor tissues, favorable biodistribution with prolonged blood retention, robust tumor uptake, and superiority to [18F]FDG in a TNBC model ...
Clemens Dobelmann, Constanze C. Schmies, Georg Wilhelm Rolshoven, Mirko Scortichini, Stefan Wagner, Andreas Isaak, Riham M. Idris, Jennifer Dabel, Lucie Grey, Karolina Losenkova, Susanne Moschütz, Haneen Al Hroub, Antje Keim, Sandra Höppner, Jouko Sandholm, Pia Boström, Maija Hollmén, Norbert Sträter, Sven Hermann, Gennady G. Yegutkin, Kenneth A. Jacobson, Sonja Schelhaas, Christa E. Müller, Anna Junker   +23 more
wiley   +2 more sources

Radioligand therapies in cancer: mapping the educational landscape in Europe

European Journal of Nuclear Medicine and Molecular Imaging, 2023
Abstract Aim We performed a systematic survey to assess the existing gaps in Europe in multidisciplinary education for integration of radioligand therapy (RLT) into cancer care and to obtain detailed information on the current limitations and key contents relevant. Methods A
Bugani, Valentina, Battistelli, Luca, Sansovini, Maddalena, Monti, Manuela, Paganelli, Giovanni, Gich, Ignasi, Flotats, Albert, Erba, Paola Anna, Blay, Jean-Yves, la Fougere, Christian, Van Poppel, Hendrik, Charalambous, Andreas, Herrmann, Ken, Giordano, Alessandro, Gyorke, Tamas, Deroose, Christophe, Matteucci, Federica, Carrio, Ignasi   +17 more
openaire   +4 more sources

Synthesis and pre-clinical evaluation of a [18F] fluoromethyl-tanaproget derivative for imaging of progesterone receptor expression [PDF]

, 2016
The estrogen receptor (ER) and progesterone receptor (PR) are over-expressed in ∼50% of breast cancer lesions, and used as biomarkers to stratify patients for endocrine therapy. Currently, immunohistochemical (IHC) assessment of these lesions from a core-
Aboagye, EO, Allott, L, Carroll, L, Kealey, S, Merchant, S, Miller, PW, Smith, G, Tittrea, V, Witney, TH   +8 more
core   +1 more source

PET imaging of steroid hormone receptor expression [PDF]

, 2015
Steroid hormone receptor (SHR) expression and changes in SHR expression compared to basal levels, whether upregulated, down-regulated, or mutated, form a distinguishing feature of some breast, ovarian, and prostate cancers.
Aboagye, EO, Allott, L, Carroll, L, Smith, G   +3 more
core   +2 more sources

PROLONGED AND INTENSE UPTAKE OF [177LU]LU-FAP-RTX IN MYOEPITHELIAL CARCINOMA: A CASE REPORT

Hematology, Transfusion and Cell Therapy
Introduction/Justification: We present a case of a 71-year-old male patient diagnosed with myoepithelial carcinoma of the pelvis and perineum, who underwent fibroblast activation protein (FAP)-directed radioligand therapy and presented long lasting tumor
Stephan Pinheiro Macedo de Souza, Ralph A. Bundschuh, Martin Hügle, Alexander Gäble, Andreas Rinscheid, Rafael Baldissera, Felipe Thome, Rafael Portugal, Alan Ribeiro, Camila Portugal, Adriana Quagliata, Constantin Lapa   +11 more
doaj   +1 more source

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management

Translational Oncology, 2022
Prostate specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed on prostate epithelial cells and is strongly upregulated in prostate cancer.
Sonia Mahajan, Ravinder K. Grewal, Kent P. Friedman, Heiko Schöder, Neeta Pandit-Taskar   +4 more
doaj   +1 more source

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines [PDF]

, 2018
Somatostatin analogs (SSA) are well-established antisecretory drugs in functionally active neuroendocrine tumors (NET). Two placebo-controlled trials have recently demonstrated significant improvement of progression-free survival under SSA treatment ...
Exner, Samantha, Grötzinger, Carsten, Prasad, Vikas, Wiedenmann, Bertram   +3 more
core   +1 more source

Quality Assurance Investigations and Impurity Characterization during Upscaling of [¹⁷⁷Lu]Lu-PSMA^I&T

Molecules, 2023
[177Lu]Lu-PSMAI&T is widely used for the radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC). Since this kind of therapy has gained a large momentum in recent years, an upscaled production process yielding multiple patient ...
Stefan Schmitl, Julia Raitanen, Stephan Witoszynskyj, Eva-Maria Patronas, Lukas Nics, Marius Ozenil, Victoria Weissenböck, Thomas L. Mindt, Marcus Hacker, Wolfgang Wadsak, Marie R. Brandt, Markus Mitterhauser   +11 more
doaj   +1 more source